Japan's Ministry of Health, Labor and Welfare last week gave the nod to several new drug indications, including Mitsubishi Tanabe's Remicade for intravenous use and indications of entero-Behcet, neuro-Behcet and vasculo-Behcet diseases when existing treatments are inadequate, a spokesman for the ministry said. The other approved new indications were for Pfizer's ($PFE) VFend, Actelion Pharmaceuticals' ($ATLN) Tracleer, and INO Therapeutics' INOflo. More